Workhorse Mini
$3,949
7–10
patients to recover price
Entry launch, smaller treatment rooms, mobile use, or first cash-pay rollout.
Practice Financial Strategy
Turn Shockwave therapy into a measurable cash-pay service line.
For practices evaluating Shockwave therapy, the upside is strongest when the service is managed as a revenue program: clear unit economics, fast payback thresholds, financing runway, and disciplined weekly metrics.
Why patients say yes
The strongest cash-pay message is practical and patient-centered: chronic pain problems, brief outpatient treatment, and limited disruption to daily activity.
Easier patient acceptance than surgical or medication-based alternatives.
Core financial signals
$400–$600
Gross revenue per patient
based on a five-treatment package
7–34
Equipment recovery range
patients across Mini, Pro, and XL models
$20.8K–$31.2K
Low-volume annual upside
from one new patient start per week
Figures are illustrative gross estimates from the source-packet assumptions and exclude staffing, financing cost, discounts, supplies, taxes, and overhead.
Unit economics
The model starts with a five-treatment series.
The financial case becomes easier to manage when the practice understands the revenue unit: one patient, one short series, one measurable gross revenue target.
Average treatment series5 treatments
First two treatments$50 each
Following three treatments$100–$200 each
Gross revenue per completed patient$400–$600
Average gross revenue per visit$80–$120
Payback by model
Recovery can happen in dozens of patients, not hundreds.
At the stated gross revenue range, the equipment recovery question becomes practical: how quickly can the practice generate its first 7 to 34 committed patient starts?
Workhorse Pro
$10,349
18–26
patients to recover price
Clinic-ready program with broader protocol and applicator flexibility.
Workhorse XL
$13,349
23–34
patients to recover price
Higher-volume outpatient growth and durability-focused throughput.
Volume sensitivity
One new patient per week still matters.
Because each patient represents a multi-session series, even low-volume adoption can create visible gross revenue. These scenarios use the $400–$600 gross revenue per patient assumption and 52 weeks per year.
1
start / week
$1,733–$2,600 / month
$20,800–$31,200 / year
2
start / week
$3,467–$5,200 / month
$41,600–$62,400 / year
3
start / week
$5,200–$7,800 / month
$62,400–$93,600 / year
5
start / week
$8,667–$13,000 / month
$104,000–$156,000 / year
8
start / week
$13,867–$20,800 / month
$166,400–$249,600 / year
Financing runway
Financing can reduce launch friction.
The financing value is not merely affordability. It is a launch runway that can help the practice build patient flow before first payments begin.
No down payment
Preserves cash for launch marketing, training, and patient education.
90-day deferred payments
Creates an estimated 13-week runway to begin building patient revenue.
Fast decision path
Materials cite 2-hour credit approval, same-day documents, and electronic signatures.
No prepayment penalty
Practices may pay off early if utilization accelerates.
Patient demand and practice fit
The business case improves when patients understand the offer.
Mayo Clinic materials describe Shockwave therapy as noninvasive and outpatient, with common benefits including no surgery, no medication, and no downtime or activity restrictions after treatment. That kind of patient-friendly explanation supports consult conversion and completion of a treatment series.
Noninvasive outpatient positioning
Brief treatment sessions
Multi-session care plans
Chronic tendon and foot/ankle relevance
Launch discipline
Treat it like a revenue program, not a device purchase.
The largest risk is not the equipment price. It is launching passively without a patient-identification process, consult script, and weekly performance review.
01
Define eligible patient categories consistent with scope of practice.
02
Package the expected treatment series and total patient cost clearly.
03
Train staff to identify internal candidates and explain the care pathway.
04
Activate the included marketing blueprint for education and follow-up.
05
Track consults, conversion, starts, completed visits, and revenue per patient.
Responsible use
Verify the details before purchase or promotion.
All revenue figures are illustrative gross estimates based on user-provided source materials. Practices should verify final equipment pricing, accessories, shipping, warranty terms, financing terms, service costs, and availability directly with the vendor or finance provider.
This webpage is for business-planning discussion only and is not medical, legal, tax, accounting, financing, or compliance advice. Device use, patient selection, claims, advertising, and scope-of-practice questions should be reviewed with qualified advisors and applicable regulatory guidance.
Sources used: NCMIC Lease Program and Equipment Finance Credit Application; Shockwave Distributors Sales Asset and Information Package; Mayo Clinic Orthopedics & Sports Medicine article; Mayo Clinic News Network Q&A; PubMed abstract on extracorporeal shockwave therapy and chronic diabetic foot ulcers; Workhorse handpiece and product comparison materials.